News
04-29-2010, 05:26 AM
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") announced that the North Central Cancer Treatment Group ("NCCTG") plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast ("mTNBC") cancer, defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2...
More... (http://mnt.to/f/3BT9)
More... (http://mnt.to/f/3BT9)